Index S&P 500
P/E -
EPS (ttm) -6.36
Insider Own 2.77%
Shs Outstand 180.00M
Perf Week -1.57%
Market Cap 9.73B
Forward P/E 47.30
EPS next Y 1.14
Insider Trans -0.01%
Shs Float 175.97M
Perf Month -3.95%
Income -1152.00M
PEG -
EPS next Q 0.51
Inst Own 95.06%
Short Float 3.86%
Perf Quarter -5.95%
Sales 4.15B
P/S 2.35
EPS this Y -84.69%
Inst Trans -7.71%
Short Ratio 3.86
Perf Half Y 35.94%
Book/sh 20.06
P/B 2.68
EPS next Y 647.55%
ROA -11.13%
Short Interest 6.80M
Perf Year 44.48%
Cash/sh 0.90
P/C 60.09
EPS next 5Y 32.83%
ROE -27.71%
52W Range 31.80 - 60.20
Perf YTD 19.72%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -13.48%
52W High -10.65%
Beta 1.21
Dividend TTM -
Quick Ratio 1.77
Sales past 5Y 12.64%
Gross Margin 19.38%
52W Low 69.15%
ATR (14) 0.55
Dividend Ex-Date -
Current Ratio 2.51
EPS Y/Y TTM -2835.82%
Oper. Margin 0.43%
RSI (14) 28.37
Volatility 1.27% 0.90%
Employees 17800
Debt/Eq 1.38
Sales Y/Y TTM -8.25%
Profit Margin -27.77%
Recom 3.11
Target Price 60.75
Option/Short Yes / Yes
LT Debt/Eq 1.37
EPS Q/Q 55.75%
Payout -
Rel Volume 1.93
Prev Close 53.61
Sales Surprise -4.32%
EPS Surprise -127.86%
Sales Q/Q 3.57%
Earnings May 08 AMC
Avg Volume 1.76M
Price 53.79
SMA20 -2.81%
SMA50 -3.75%
SMA200 9.72%
Trades
Volume 3,407,462
Change 0.34%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-16-23 Upgrade
Robert W. Baird
Neutral → Outperform
$45 → $53
Sep-05-23 Upgrade
Argus
Hold → Buy
$62
Jul-20-23 Initiated
Wells Fargo
Equal Weight
$43
Jul-05-23 Resumed
JP Morgan
Neutral
$45
Jun-14-23 Downgrade
Jefferies
Buy → Hold
$45 → $44
May-22-23 Downgrade
JP Morgan
Overweight → Neutral
$90 → $45
May-15-23 Downgrade
Deutsche Bank
Buy → Hold
$55 → $29
May-08-23 Downgrade
BofA Securities
Neutral → Underperform
$28
Apr-17-23 Downgrade
Robert W. Baird
Outperform → Neutral
$82 → $53
Apr-14-23 Downgrade
William Blair
Outperform → Mkt Perform
Apr-10-23 Upgrade
Deutsche Bank
Hold → Buy
$79 → $88
Apr-03-23 Downgrade
Barclays
Overweight → Equal Weight
$70
Dec-19-22 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Nov-07-22 Downgrade
Argus
Buy → Hold
Nov-02-22 Downgrade
BofA Securities
Buy → Neutral
$125 → $60
Dec-16-21 Initiated
Barclays
Overweight
$160
Dec-10-20 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
$120
Jun-25-20 Initiated
Argus
Buy
$100
Apr-21-20 Initiated
RBC Capital Mkts
Outperform
$65
Mar-02-20 Initiated
Deutsche Bank
Hold
Show Previous Ratings
May-29-24 09:07AM
May-27-24 03:02AM
May-16-24 02:26PM
May-14-24 10:33AM
May-13-24 11:46AM
11:20AM
Loading…
11:20AM
May-09-24 01:31PM
01:05AM
12:53AM
May-08-24 11:37PM
07:30PM
06:24PM
(Associated Press Finance)
04:15PM
May-03-24 10:12AM
09:50AM
(The Wall Street Journal)
08:58AM
Loading…
08:58AM
08:36AM
08:16AM
04:17AM
04:02AM
May-02-24 01:08PM
11:31AM
08:19AM
08:02AM
06:18AM
Apr-17-24 08:19PM
Apr-16-24 09:53AM
Apr-11-24 02:21AM
Apr-10-24 11:03PM
Apr-08-24 06:31AM
06:28AM
Loading…
06:28AM
05:55AM
Apr-05-24 11:08PM
Mar-28-24 01:15PM
Mar-11-24 12:44PM
Mar-09-24 01:00PM
Mar-08-24 07:11AM
Mar-07-24 10:41AM
10:31AM
08:00AM
Feb-27-24 10:50AM
Feb-14-24 04:43PM
Feb-13-24 12:32AM
Feb-10-24 09:53AM
Feb-09-24 11:28AM
09:30AM
09:13AM
08:37AM
08:14AM
08:11AM
(Associated Press Finance)
08:03AM
07:59AM
Feb-08-24 06:37AM
05:48AM
04:53AM
Feb-07-24 12:55PM
12:23PM
11:53AM
07:51AM
Feb-06-24 05:23PM
02:44PM
12:22PM
(The Wall Street Journal)
11:13AM
09:47AM
08:37AM
06:19AM
Feb-05-24 06:35PM
(Morningstar Research) +9.74%
06:25PM
06:07PM
04:35PM
(Investor's Business Daily)
04:32PM
02:41PM
02:03PM
01:46PM
(Investor's Business Daily)
01:21PM
01:04PM
(The Wall Street Journal)
12:38PM
(The Wall Street Journal)
12:27PM
12:13PM
11:04AM
10:57AM
10:36AM
10:35AM
10:29AM
10:26AM
09:03AM
07:59AM
07:40AM
06:56AM
(The Wall Street Journal)
06:47AM
06:19AM
06:18AM
06:16AM
06:07AM
06:04AM
06:00AM
Jan-31-24 05:55AM
05:24AM
05:03AM
04:40AM
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gunther Scott SVP, Quality & Reg. Affairs Mar 15 '24 Sale 56.20 387 21,749 29,506 Mar 19 01:38 PM Ryan Michelle R Director Aug 31 '23 Buy 49.98 1,000 49,980 1,979 Sep 05 06:00 PM GREISCH JOHN J Executive Chair Aug 30 '23 Buy 50.24 21,000 1,055,040 34,000 Sep 01 01:52 PM Maselli Alessandro President & CEO Aug 24 '23 Sale 44.54 2,071 92,245 88,004 Aug 25 07:16 PM Fasman Steven L EVP & Chief Admin Officer Aug 24 '23 Sale 44.65 817 36,479 73,789 Aug 25 07:02 PM Gennadios Aristippos Group Pres. Pharma & Consumer Aug 24 '23 Sale 44.49 396 17,618 96,552 Aug 25 07:05 PM Grippo Michael J SVP, Strategy & Corp. Dev. Aug 24 '23 Sale 44.50 390 17,355 24,449 Aug 25 07:08 PM Pravda Ricardo Chief Transformation Officer Aug 24 '23 Sale 44.47 379 16,854 30,224 Aug 25 06:37 PM Hopson Ricky Pres. Clinical Dev Supply Div Aug 24 '23 Sale 44.56 276 12,299 22,040 Aug 25 06:52 PM Gunther Scott SVP, Quality & Reg. Affairs Aug 24 '23 Sale 44.57 269 11,989 29,932 Aug 25 07:12 PM Carletti Lorenzo SVP Global Ops Ph & Cons Hlth Aug 24 '23 Sale 44.71 216 9,657 8,746 Aug 25 06:58 PM Lickfold Charles SVP, CIO Aug 24 '23 Sale 44.72 190 8,497 11,339 Aug 25 06:45 PM Hawkeswood Thomas W Pres. Pharma Prod Delivery Div Aug 24 '23 Sale 44.72 147 6,574 7,533 Aug 25 06:48 PM Hunt Patricia Pres. Consumer Health Div Aug 24 '23 Sale 44.77 106 4,746 11,289 Aug 25 06:39 PM Arnold Jonathan SVP, CCO & Div. Head BioP Del. Aug 24 '23 Sale 44.87 87 3,904 57,399 Aug 25 06:56 PM Fasman Steven L EVP & Chief Admin Officer Aug 01 '23 Sale 47.05 1,637 77,026 60,216 Aug 03 04:02 PM Maselli Alessandro President & CEO Aug 01 '23 Sale 47.13 1,485 69,995 86,101 Aug 03 05:05 PM Carletti Lorenzo SVP Global Ops Ph & Cons Hlth Aug 01 '23 Sale 47.77 383 18,296 4,602 Aug 03 04:16 PM Gennadios Aristippos Group Pres. Pharma & Consumer Aug 01 '23 Sale 47.59 281 13,373 86,488 Aug 03 04:21 PM Grippo Michael J SVP, Strategy & Corp. Dev. Aug 01 '23 Sale 47.72 276 13,171 17,516 Aug 03 04:30 PM Pravda Ricardo Chief Transformation Officer Aug 01 '23 Sale 47.56 269 12,793 19,739 Aug 03 05:13 PM Hawkeswood Thomas W Pres. Pharma Prod Delivery Div Aug 01 '23 Sale 47.97 258 12,376 5,106 Aug 03 04:41 PM Hopson Ricky Pres. Clinical Dev Supply Div Aug 01 '23 Sale 47.86 195 9,333 16,257 Aug 03 04:47 PM Gunther Scott SVP, Quality & Reg. Affairs Aug 01 '23 Sale 47.90 190 9,101 23,798 Aug 03 04:37 PM Hunt Patricia Pres. Consumer Health Div Aug 01 '23 Sale 47.95 161 7,720 9,154 Aug 03 04:51 PM Lickfold Charles SVP, CIO Aug 01 '23 Sale 47.90 135 6,466 5,570 Aug 03 05:00 PM Arnold Jonathan SVP, CCO & Div. Head BioP Del. Aug 01 '23 Sale 47.80 62 2,964 55,896 Aug 03 04:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite